This inventor holds 5 USPTO granted patents and 1 published patent application and 2 EPO patents. Top assignee: Novartis Ag. Active years: 2012-2015.
Company Filing History:
Years Active: 2012-2015
Title: The Innovative Contributions of Markus Bänziger
Introduction
Markus Bänziger is a notable inventor based in Bubendorf, Switzerland. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that serve as NEP-inhibitors. With a total of 5 patents to his name, Bänziger's work is recognized for its potential impact on medical science.
Latest Patents
One of his latest patents involves a process for preparing 5-biphenyl-4-amino-2-methyl pentanoic acid. This invention relates to pyrrolidin-2-ones, which are crucial in the preparation of NEP-inhibitors. The patent details methods for their preparation and their use in synthesizing N-(3-carboxyl-1-oxopropyl)-(4S)-(p-phenylphenylmethyl)-4-amino-(2R)-methyl butanoic acid ethyl ester or its salt. This innovative approach showcases Bänziger's commitment to advancing pharmaceutical research.
Career Highlights
Markus Bänziger is currently employed at Novartis AG, a leading global healthcare company. His role at Novartis allows him to collaborate with other experts in the field, further enhancing his contributions to pharmaceutical innovations. His work is characterized by a focus on developing effective treatments that can improve patient outcomes.
Collaborations
Throughout his career, Bänziger has worked alongside esteemed colleagues such as David Hook and Thomas Ruch. These collaborations have fostered an environment of innovation and creativity, leading to the successful development of new pharmaceutical compounds.
Conclusion
Markus Bänziger's contributions to the field of pharmaceuticals through his patents and collaborations highlight his role as an influential inventor. His work continues to pave the way for advancements in medical treatments, showcasing the importance of innovation in healthcare.